Nuvectis Pharma, Inc. (NVCT)
Nasdaq: NVCT · Pharmaceutical Preparations · Fort Lee, NJ · filing with the SEC since 2021
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Report filed | Feb 11, 2026 | Feb 25, 2025 | Mar 5, 2024 | Mar 8, 2023 | Mar 23, 2022 |
| Research and development | 18,153 | 12,918 | 15,380 | 13,227 | 9,545 |
| General and administrative | 9,421 | 6,929 | 7,517 | 6,007 | 3,349 |
| Operating income | -27,574 | -19,847 | -22,897 | -19,234 | -12,894 |
| Net income including non-controlling interests | -26,442 | -19,000 | -22,260 | -19,085 | -12,890 |
| Net income | -26,442 | -19,000 | -22,260 | -19,085 | -12,890 |
| Net income to common shareholders | -28,871 | -19,000 | -22,260 | -19,085 | -12,890 |
| Earnings per share, basic | -1.32 | -1.11 | -1.43 | -1.51 | -3.02 |
| Earnings per share, diluted | -1.32 | -1.11 | -1.43 | -1.51 | -3.02 |
| Weighted average shares, basic | 21,812,716 | 17,113,169 | 15,556,655 | 12,657,651 | 4,268,285 |
| Weighted average shares, diluted | 21,812,716 | 17,113,169 | 15,556,655 | 12,657,651 | 4,268,285 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding